Review




Structured Review

Partec visitect cd4 advanced hiv disease assay
Visitect Cd4 Advanced Hiv Disease Assay, supplied by Partec, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/visitect cd4 advanced hiv disease assay/product/Partec
Average 86 stars, based on 1 article reviews
visitect cd4 advanced hiv disease assay - by Bioz Stars, 2026-06
86/100 stars

Images



Similar Products

86
Partec visitect cd4 advanced hiv disease assay
Visitect Cd4 Advanced Hiv Disease Assay, supplied by Partec, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/visitect cd4 advanced hiv disease assay/product/Partec
Average 86 stars, based on 1 article reviews
visitect cd4 advanced hiv disease assay - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

90
Omega Diagnostics visitect cd4 advanced hiv disease lfa
The basic indicators for advanced <t> HIV </t> disease care.
Visitect Cd4 Advanced Hiv Disease Lfa, supplied by Omega Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/visitect cd4 advanced hiv disease lfa/product/Omega Diagnostics
Average 90 stars, based on 1 article reviews
visitect cd4 advanced hiv disease lfa - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


The basic indicators for advanced  HIV  disease care.

Journal: Southern African Journal of HIV Medicine

Article Title: Establishing targets for advanced HIV disease: A call to action

doi: 10.4102/sajhivmed.v22i1.1266

Figure Lengend Snippet: The basic indicators for advanced HIV disease care.

Article Snippet: The roll-out of the WHO-approved point-of-care VISITECT CD4 Advanced HIV Disease LFA by Omega Diagnostics (Alva, United Kingdom) provides an instrument-free, semi-quantitative result for CD4 (greater than or less than 200 cells/µL), which should be rapidly expanded; however, feasibility studies for point-of-care use in routine care settings are needed to inform placement and scale-up.

Techniques: Infection